Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Current Deferred Revenue: 2018-2025

Historic Current Deferred Revenue for Bicycle Therapeutics (BCYC) over the last 7 years, with Sep 2025 value amounting to $12.3 million.

  • Bicycle Therapeutics' Current Deferred Revenue rose 7.76% to $12.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.3 million, marking a year-over-year increase of 7.76%. This contributed to the annual value of $10.2 million for FY2024, which is 59.20% down from last year.
  • Latest data reveals that Bicycle Therapeutics reported Current Deferred Revenue of $12.3 million as of Q3 2025, which was down 16.14% from $14.6 million recorded in Q2 2025.
  • In the past 5 years, Bicycle Therapeutics' Current Deferred Revenue ranged from a high of $29.8 million in Q2 2023 and a low of $8.7 million during Q2 2021.
  • Its 3-year average for Current Deferred Revenue is $17.8 million, with a median of $14.6 million in 2025.
  • Per our database at Business Quant, Bicycle Therapeutics' Current Deferred Revenue skyrocketed by 142.78% in 2021 and then crashed by 60.95% in 2024.
  • Quarterly analysis of 5 years shows Bicycle Therapeutics' Current Deferred Revenue stood at $19.3 million in 2021, then climbed by 5.94% to $20.4 million in 2022, then climbed by 22.33% to $25.0 million in 2023, then tumbled by 59.20% to $10.2 million in 2024, then grew by 7.76% to $12.3 million in 2025.
  • Its last three reported values are $12.3 million in Q3 2025, $14.6 million for Q2 2025, and $12.5 million during Q1 2025.